Tomohiro Tanaka

Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial

Toyoaki Hida, Hiroshi Nokihara, Masashi Kondo et al. · The Lancet · 2017 · 895 citations

Medicine, Randomised Phase 3, Pathology +8

Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study

Shirish M. Gadgeel, Leena Gandhi, Gregory J. Riely et al. · The Lancet Oncology · 2014 · 688 citations

Phase 1/2, Neuro-oncology, Dose-finding Portion +9

CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 study

Takashi Seto, Katsuyuki Kiura, Makoto Nishio et al. · The Lancet Oncology · 2013 · 576 citations

Non-small-cell Lung Cancer, Medicine, Pathology +9

Bivalent Ligands of CXCR4 with Rigid Linkers for Elucidation of the Dimerization State in Cells

Tomohiro Tanaka, Wataru Nomura, Tetsuo Narumi et al. · Journal of the American Chemical Society · 2010 · 77 citations

Biochemistry, G Protein-coupled Receptor, Medicine +15

Alectinib (ALC) versus crizotinib (CRZ) in ALK-inhibitor naive <i>ALK</i>-positive non-small cell lung cancer (<i>ALK+</i> NSCLC): Primary results from the J-ALEX study.

Hiroshi Nokihara, Toyoaki Hida, Masashi Kondo et al. · Journal of Clinical Oncology · 2016 · 73 citations

J-alex Study, Versus Crizotinib, Alc Arm +15